A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
about
Pharmacogenomics of breast cancer therapy: an updateThe Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.Genetic polymorphisms in estrogen-related genes and the risk of breast cancer among Han Chinese women.The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancerInfluence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patientsPlacental Aromatase Is Deficient in Placental Ischemia and Preeclampsia.Understanding the mechanisms of aromatase inhibitor resistance.Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.Association of CYP8A1 (Prostacyclin I2 synthase) polymorphism rs5602 with breast cancer in Mexican woman.Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.Impact of aromatase genetic variation on hormone levels and global outcome after severe TBI.A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer.The rs4646 and rs12592697 Polymorphisms in CYP19A1 Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds.Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.Pharmacogenetics of aromatase inhibitors.Pharmacogenomics of osteoporosis: a pathway approach.Pharmacogenomics of third-generation aromatase inhibitors.Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators
P2860
Q27006783-9C7D8E5B-C7E3-4C77-B464-D8EDE9D4A3BEQ30234511-B3710215-E429-45CC-B786-8241B3F1D5ABQ34558902-74E6DF03-EF38-4141-B132-DB6FFE5CE5ECQ35139194-B21FC957-7AEF-4EE9-859C-F5439A357F6FQ35202833-4716924A-7FF2-4561-9E5D-9562CFBA7CBFQ35661622-A230D51D-0F4A-41B4-BEF8-50215D496DACQ35842073-8ADEC4EC-CFB9-44F4-8903-759CE55C9A1DQ35854143-3A7DCEB2-9105-4626-AC80-9290CC1AC19FQ35879741-387599EF-E1C6-4BC3-A0DC-66505EA599EDQ35974459-07B2A92D-1B4E-4F79-BC96-1EC8A117F8CFQ36131559-ED7107D9-C434-4889-A5A7-3A89093BF69FQ36393053-7F315452-AF2B-495A-8B0E-D08F851BE943Q36484937-10BEDA44-EB11-4628-854C-5FC87D674A97Q36578211-D427413A-0CF9-4EB6-A4EE-4749ADD1F954Q36603917-FF5B71F2-B3D9-4DF6-9ADD-9C4FB25033DEQ36606068-190B64AB-7CE7-46EA-80E4-C270621483B2Q36688742-2E60B84B-AAE3-4643-B99A-E50B8C619D11Q36878734-A117AAA7-52A1-41DF-AB9F-E385FD0000A3Q36979050-D63DAFB8-BE34-45A0-8F27-C0151B427BE5Q37089911-14EB5477-3853-4E17-8FF4-030EBB5EFA2FQ37225249-EBEDF274-121C-44C6-99FB-CA0AFF55C079Q37353704-DAF01576-F6E7-49C4-A165-5B48A67A6245Q37463634-F3CA1E69-FB4C-453A-9A11-5E189110B8A1Q37662607-7BEB9E4A-DC50-4D93-8171-95305B11D696Q37665513-D42B71FD-CDE4-4425-BD80-A8CF5D44C69DQ38003704-D7434F24-D402-4819-A6A7-AA271567315BQ38010749-5C4DE6C5-E9A2-4E7B-93F9-8C9156545625Q38010777-C941CBC1-9767-41C2-94B6-C604ECF0856AQ38028797-924B92E6-ED3D-40AD-A568-368F02CA2308Q38103593-D001326B-8876-47D7-96EE-1245E09E9E43Q38295718-F23060A7-142B-4427-8DB6-B097548F17FEQ38305705-F376E2CD-8699-4444-8D64-2E7FDA3EDFEAQ38737784-FFDC079A-C4BF-4146-B59F-B9E3903501B6Q38739248-8A9E4A60-AE38-4908-B6E4-594A348AF71BQ38851505-88191E9C-9AD6-422F-9499-DA5387116FCEQ44502008-B0532810-3A46-476A-BB02-BD9A106BF4DCQ46617999-6E8D1294-A2EC-42A5-B93F-8261C52DAF65Q57568320-F295F7AF-F059-442C-82B4-5BB70E491DB2
P2860
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A polymorphism at the 3'-UTR r ...... onse to neoadjuvant letrozole.
@ast
A polymorphism at the 3'-UTR r ...... onse to neoadjuvant letrozole.
@en
type
label
A polymorphism at the 3'-UTR r ...... onse to neoadjuvant letrozole.
@ast
A polymorphism at the 3'-UTR r ...... onse to neoadjuvant letrozole.
@en
prefLabel
A polymorphism at the 3'-UTR r ...... onse to neoadjuvant letrozole.
@ast
A polymorphism at the 3'-UTR r ...... onse to neoadjuvant letrozole.
@en
P2093
P2860
P356
P1433
P1476
A polymorphism at the 3'-UTR r ...... onse to neoadjuvant letrozole.
@en
P2093
Amparo Ruiz-Simon
Ana Calatrava
Angel Guerrero-Zotano
Antonio Fernandez-Serra
Antonio Llombart-Bosch
Antonio Llombart-Cussac
Carlos Vazquez Albaladejo
Joaquin Gavila
Jose A Lopez-Guerrero
Jose Cervera-Deval
P2860
P2888
P356
10.1186/1471-2407-10-36
P407
P577
2010-02-09T00:00:00Z
P5875
P6179
1038604088